Clinical Trial Detail

NCT ID NCT03127098
Title QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements no
Sponsors NantCell, Inc.
Indications

colon cancer

rectum cancer

Advanced Solid Tumor

Therapies

ALT-803 + ETBX-011

Age Groups: adult senior

No variant requirements are available.